Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival

Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival

Guardado en:
Detalles Bibliográficos
Autores principales: Hui Zheng, Eirini Pectasides, Mohamed Uduman, Charles S Fuchs, James M Cleary, Adam J Bass, Jérémy Augustin, Leonie K de Klerk, Anuj K Patel, Sarah Derks, Nihal Raman, Fahire G Akarca, Nadine J McCleary, Douglas A Rubinson, Jeffrey W Clark, Bridget Fitzpatrick, Lauren K Brais, Megan E Cavanaugh, Amanda J Rode, Melissa G Jean, Patrick H Lizotte, Matthew J Nazzaro, Peter C Enzinger
Formato: article
Lenguaje:EN
Publicado: BMJ Publishing Group 2021
Materias:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/88b5dffda1124385a9d172a7073bce20
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/88b5dffda1124385a9d172a7073bce20

Ejemplares similares